Urothelial Carcinoma Treatment Market Overview
Urothelial Carcinoma Treatment Market size is estimated to reach $4.6 billion by 2027, growing at an estimated CAGR of 7.8% during the forecast period 2022-2027. Bladder cancer happens when the cells in the bladder begin to grow abnormally or unmanageably. The most typical kind of bladder cancer is termed urothelial carcinoma. With this cancer, abnormal growth takes place on the inside lining (urothelium) of the bladder. As the ailment advances, it may expand. It can expand to the areas around the bladder or to additional portions of the body (metastasis). This is termed advanced urothelial carcinoma. The increasing investments in R&D activities pertaining to novel cancer treatment and the rising application of biopsy methods and urine cytology are set to drive the Urothelial Carcinoma Treatment Market. The different awareness programs performed by government and non-government organizations pertaining to bladder cancer are set to propel the growth of the Urothelial Carcinoma Treatment Industry during the forecast period 2022-2027. This represents the Urothelial Carcinoma Treatment Industry Outlook.
Urothelial Carcinoma Treatment Market Report Coverage
The “Urothelial Carcinoma Treatment Market Report - Forecast (2022-2027)” by Industry ARC, covers an in-depth analysis of the following segments in the Urothelial Carcinoma Treatment Market.
- Geographically, North America (Urothelial Carcinoma Treatment market share) accounted for the highest revenue share in 2021. It is also expected to dominate the market over the period 2022-2027 due to the increasing predominance of bladder cancer requiring the application of biopsy methods and urine cytology in the North American region.
- Urothelial Carcinoma Treatment Market growth is being driven by the rising count of novel cases of bladder cancer which may involve the application of biopsy and urine cytology and the burgeoning recognition of targeted therapies across the world. However, the existence of generic medications in the market and the soaring cost of R&D financing for the development of a novel medication for treatment are some of the major factors hampering the growth of the Urothelial Carcinoma Treatment Market.
- Urothelial Carcinoma Treatment Market Detailed Analysis of the Strengths, Weaknesses and Opportunities of the prominent players operating in the market would be provided in the Urothelial Carcinoma Treatment Market report.
Urothelial Carcinoma Treatment Market Segment Analysis - by Cancer Type
The Urothelial Carcinoma Treatment Market based on cancer type can be further segmented into Papillary Carcinoma and Flat Carcinoma. The Papillary Carcinoma Segment held the largest Urothelial Carcinoma Treatment market share in 2021. This growth is caused by the increasing count of cases involving urothelial neoplasia. It includes a range of tumors with distinct biological behaviors. The most typical urothelial neoplasm is the low grade superficial papillary carcinoma or papilloma which may recur many times but does not lead to considerable morbidity or mortality. The rising number of cases of papillary Urothelial Carcinoma owing to arsenic exposure and some genetic mutations further propelling the growth of the Papillary Carcinoma segment.
Furthermore, the Papillary Carcinoma segment is estimated to grow with the fastest CAGR of 9.1% during the forecast period 2022-2027 owing to the slightly greater incidence rate of papillary carcinoma at 3 per 100,000 individuals per year and the male-to-female ratio being 5:1.
Urothelial Carcinoma Treatment Market Segment Analysis - by Treatment
The Urothelial Carcinoma Treatment Market based on treatment can be further segmented into Surgery, Chemotherapy, Radiation Therapy and Immunotherapy. The Chemotherapy Segment held the largest Urothelial Carcinoma Treatment market share in 2021. This growth is fuelled by the surging application of chemotherapy for patients with metastatic urothelial cancer of the bladder and urinary tract. A cisplatin-based combination chemotherapy regimen is the favored initial therapy for cisplatin candidates with metastatic urothelial cancer of the bladder and urinary tract. Significantly, a tiny proportion of patients with distant metastases in the nodes or lungs may be cured by combination chemotherapy. The extensive application of Intravesical chemotherapy and Systemic chemotherapy for bladder cancer is further propelling the growth of this segment.
Furthermore, the Radiation Therapy segment is estimated to grow with the fastest CAGR of 8.3% during the forecast period 2022-2027. This is due to the fact that the combination of radiation therapy and chemotherapy for metastatic urothelial carcinoma is connected with a higher rate of overall survival in comparison with chemotherapy only.
Urothelial Carcinoma Treatment Market Segment Analysis - by Geography
The Urothelial Carcinoma Treatment Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. North America (Urothelial Carcinoma Treatment Market) held the largest Urothelial Carcinoma Treatment market share with 39% of the overall market in 2021. The growth of this region is owing to the rising count of cases pertaining to bladder cancer in North America. Radical cystectomy is the suggested treatment for bladder cancer that has attacked the muscle of the bladder. The surging awareness and well-entrenched healthcare infrastructure are further propelling the growth of the Urothelial Carcinoma Treatment Industry, thereby contributing to the Urothelial Carcinoma Treatment Industry Outlook in the North American region.
The Asia-Pacific region is expected to have the fastest CAGR over the forecast period 2022-2027. This growth is owing to factors like the increasing patient pool being diagnosed with Urothelial Carcinoma that requires the application of biopsy and urine cytology in the Asia-Pacific region. The emerging healthcare industry in countries like India and China is further fuelling the progress of the Urothelial Carcinoma Treatment Industry, thereby contributing to the Urothelial Carcinoma Treatment Industry Outlook in the Asia-Pacific region.
Urothelial Carcinoma Treatment Market Drivers
Surging Applications of Urine Biomarkers:
Of 14 case-control investigations inspecting single protein biomarkers within a meta-analysis, these biomarkers demonstrated the highest sensitivity and specificity for bladder cancer: ORM1 has a sensitivity of 92%, a specificity of 94% and a ROC of 0.965 and HTRA1 has a sensitivity and specificity of 93% and 96%, respectively. Urine biomarkers have promising uses in individuals in whom bladder cancer is suspected based on the existence of hematuria, overactive bladder symptoms or an extremely high risk of tumor. Urine biomarkers may also have a role in discovering recurrences in patients who have been treated for non-muscle-invasive diseases. They may also be utilized in the assessment of upper tract radiographic abnormalities and for monitoring patients after treatment of ureteral or renal pelvic transitional cell carcinoma. Urine cytology is a significant screening tool in the diagnosis of high-grade urothelial carcinoma. Diagnosis in urine samples adheres to criteria outlined by The Paris System for Reporting Urinary Cytology (TPS). The ureteroscopic biopsy is an integral portion of the diagnosis of urothelial carcinoma of the upper urinary tract. The surging applications of Urine Biomarkers are fuelling the growth of the Urothelial Carcinoma Treatment Industry, thereby contributing to the Urothelial Carcinoma Treatment Industry Outlook during the forecast period 2022-2027.
Soaring Applications of Transurethral Bladder Tumor Resection:
Transurethral bladder tumor resection can include both biopsy and tumor elimination (resection). As the procedure goes by way of the urethra, no incisions are essential. The surgery can avert cancer from intruding on the muscle wall. TURBT is the procedure performed to diagnose and treat early-stage bladder cancer at the same time. The initials stand for transurethral resection of a bladder tumor. This procedure is the first-line diagnostic test and treatment for bladder cancer. Men are almost four times more probable than women to be diagnosed with this kind of cancer. Most people have bladder cancer that has not attacked the muscle wall when initially diagnosed. Nearly everyone diagnosed with bladder cancer would endure bladder tumor biopsy and resection. A biopsy is a procedure in which a physician takes a tissue sample from the area where cancer may be present. At the time of the biopsy procedure, the physician also would attempt to eliminate the cancerous growth. This is termed resectioning. The complete procedure for bladder tumor biopsy and resection is termed transurethral resection of bladder tumor (TURBT) or transurethral bladder tumor resection. In certain cases, a second TURBT may be performed 2 to 6 weeks later, like when the bladder tumor was not entirely eliminated the first time or for more advanced tumors. TURBT is most successful for patients with tiny, single tumors that have not spread to other tissues. Success rates in these cases are about 60 to 70 percent. The soaring applications of transurethral bladder tumor resection are therefore driving the growth of the Urothelial Carcinoma Treatment Market during the forecast period 2022-2027.
Urothelial Carcinoma Treatment Market Challenge:
High Cost of Urothelial Carcinoma Treatment:
Radical cystectomy (RC) is an efficient curative treatment for high-grade and muscle-invasive bladder cancer. Although radical cystectomy is thought-out to be the gold standard for muscle-invasive urothelial carcinoma (UC) of the bladder, the operation is filled with serious perioperative morbidity with a complication rate ranging from 34% to 52%. Given the nature/biology of the ailment, operative time, hospital stay and complication profile, UC is expensive from a health services view. Lymph node dissection is now accepted as a mandatory step of surgery for localized muscle-invasive bladder urothelial cancer management. Contrary to urothelial carcinoma of the bladder, there is no guideline-based consensus on whether a lymph node dissection (LND) needs to be carried out at the time of radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC). Variable lymphatic drainage based on primary tumor location, dearth of prospective trials and hardships in establishing a risk-adapted approach to lymph node dissection for UTUC are all challenges to the development of an established approach. These issues are hampering the growth of the Urothelial Carcinoma Treatment Market.
Urothelial Carcinoma Treatment Industry Outlook
Novel product launches, clinical trial pipelines, product approvals, patents, technology timeline curves, mergers, agreements, acquisitions and investments in R&D activities are key strategies adopted by players in the Urothelial Carcinoma Treatment Market. The top 10 companies in the Urothelial Carcinoma Treatment market are:
- Merck & Co. Inc.
- F. Hoffmann-La Roche Ltd.
- AstraZeneca PLC.
- Bristol-Myers Squibb Company
- Novartis AG.
- Pfizer Inc.
- GlaxoSmithKline plc.
- Dendreon Pharmaceuticals LLC.
- Eisai Co. Ltd.
- Genentech, Inc.
- In August 2021, Merck declared a label update for KEYTRUDA, Merck’s anti-PD-1 therapy, for its indication in first-line advanced urothelial carcinoma (bladder cancer) in the U.S. The U.S. Food and Drug Administration (FDA) has transformed this indication from a quick to a full (regular) approval.
- In June 2020, Merck and Pfizer Inc. declared that the US Food and Drug Administration (FDA) had certified the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab) for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not advanced with first-line platinum-containing chemotherapy.
- In June 2020, Merck declared that the Phase 3 KEYNOTE-361 trial assessing KEYTRUDA, Merck’s anti-PD-1 therapy, in integration with chemotherapy for the first-line treatment of patients with advanced or metastatic urothelial carcinoma (bladder cancer) did not conform to its pre-specified dual primary endpoints of overall survival (OS) or progression-free survival (PFS), in comparison with the standard of care chemotherapy.
Report Code: HCR 0708
Report Code: HCR 0261
Report Code: HCR 0302
For more Lifesciences and Healthcare Market reports, please click here